Gastroprotection in the treatment of erosive and ulcerative lesions of the stomach and small intestine
https://doi.org/10.31146/1682-8658-ecg-169-9-17-26
Abstract
In article the reasons of erosive and ulcer injuries of a stomach, a small intestine are described. Special attention is paid to intake of nonsteroid anti-inflammatory medicines, microcirculation violation. Side effects of nonsteroid anti-inflammatory medicines and inhibitors of a proton pomp are in detail considered. Groups of patients with erosive and ulcer injuries of a stomach, small intestine with dyspepsia to which purpose of inhibitors of a proton pomp is not shown are allocated. Rebamipide can be appointed for prevention and treatment of erosive and ulcer injuries of a stomach, a small intestine with dyspepsia, both with inhibitors of a proton pomp, and in the form of monotherapy for the purpose of a gastroprotection to patients when use of inhibitors of a proton pomp is inexpedient. The gastroprotection algorithm depending on a condition of a gastric acid secretion of patients is offered.
About the Authors
E. Yu. Plotnikova
Federal State Budgetary Institution of Higher Education Kemerovo state medical University of the Ministry of health of Russia
Russian Federation
Russian Federation
Ekaterina Yu. Plotnikova, MD, Professor of the Department of training of primary care physicians, head of the course of
clinical gastroenterology, 650056, Kemerovo, Voroshilov street, 22A
L. G. Vologdanina
Federal State Budgetary Institution of Higher Education Perm state medical University. academician E. A. Wagner, Ministry of health of Russia
Russian Federation
Russian Federation
Lyudmila G. Vologdanina, Ph. D., associate Professor of the Department of faculty therapy № 1, 614990, Perm region, Perm, 26 Petropavlovsk street
A. G. Korotkevich
State doctors improvement Institute of Novokuznetsk — a branch of FGBOU DPO RMAPO Ministry of health of Russia
Russian Federation
Russian Federation
Alexey G. Korotkevich, MD, Professor, head of the Department of endoscopy, 654005, Kemerovo region, Novokuznetsk, Avenue of Builders, d. 5
T. Yu. Gracheva
Federal State Budgetary Institution of Higher Education Kemerovo state medical University of the Ministry of health of Russia
Russian Federation
Russian Federation
Tatiana Yu. Gracheva, Ph. D., head. Department of forensic medicine and medical law, 650056, Kemerovo, Voroshilov street, 22A
References
1. Solovyova, G. A. Erosion of a stomach there is a separate nosological form or universal reaction of a mucous membrane to damage? Internal medicine. 2007; 3: 96–99.
2. Zhurakhovskaya D. V., Loskutova E. E., Vinogradova I. A. The marketing analysis of the pharmaceutical market of nonsteroid anti-inflammatory medicines at the regional level. Modern problem sof science and education. 2014; 2. URL: http://science-education.ru/ru/article/view?id=12853
3. Nasonov E. L., Tsvetkova E. S., Balabanova R. M., etc. New aspects of anti-inflammatory therapy of rheumatic diseases: theoretical prerequisites and clinical application of a meloksikam. Wedge. medicine. 1996; 4: 4–8.
4. Karateev A. E., Nasonov E. L., Yakhno N. N., et al. Clinical recommendations «Rational use of nonsteroidanti-inflammatory medicines (NSAIDs) in clinical practice». Modern rheumatology. 2015;9(1): 4–23. https://doi.org/10.14412/1996–7012–2015–1–4–23.
5. Shchyokino E. G., Drogovoz S. M., Terrible V. V. NPVS – security concerns. Pharmacist. 2003; 4: 8–11.
6. Karateev A. E. Nimesulid: myths and reality. Reference book by the polyclinic doctor. 2013; 4: 56–61.
7. Shavlovsky O. A. Amtolmetinguatsit: experience of application in clinical practice. Reference book by the polyclinic doctor. 2014; 7: 54–58.
8. Tavella A., Ursini G. Studio clinico sull’attivita antiinflamatoria e sulla tollerabilita gastro-enterica di amtolmetineguacil, un nuovo FANS, in confronto a diclofenac su pazienti anziani con patologie osteoarticolari. Clin. Ter. 1997; 148: 543–548.
9. Belisari A., Mantovani L. G. Cost-benefi t analysis of amtolmetin-guacil. Clin Drug Invest. 2001;21(1): 47–58.
10. Naumov A. V., Semyonov P. A. Pain in Russia: facts and conclusions. Consilium Medicum. 2010; 02: 42–48.
11. Plotnikova E. Yu., Zolotukhina V. N., Merzlyakov S. P., Resident of Vologda L. G., Sinkova M. A. Non steroid anti-inflammatory medicines at the vertebrogennykh pain syndromes – what to choose? Comparativere search. Nervous diseases. 2018; 2: 38–42.
12. Chibyeva L. G., Fedotova A. P., Vasilyev N. N., Nikolaeva K. M., Nikolaeva V. M. The gastroduodenal damages induced by intake of nonsteroid anti-inflammatory medicines in the conditions of the Sakha (Yakutia) Republic. SVFU bulletin. 2010; 7(4): 41–46.
13. Derry S, Moore R, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Sys Rev. 2012; 12: 9. CD007400 47.
14. Sostres C, Gargallo C, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther, 2013; 15(3): 3.
15. Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013 Oct; 68(10):1219–32. doi: 10.1111/all.12260.
16. White A.A., Stevenson D. D. Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization. Semin Respir Crit Care Med. 2012 Dec;33(6):588–94. doi: 10.1055/s-0032–1325618.
17. Boghossian T.A., Rashid F. J., Thompson W., Welch V., Moayyedi P., Rojas-Fernandez C., Pottie K., Farrell B. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Systematic Review – Intervention Version published: 16 March 2017. https://www.cochranelibrary.com/cdsr/ doi/10.1002/14651858.CD011969.pub2/full
18. Linsky A., Gupta K., Lawler E. V., Fonda J. R., Hermos J. A. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170(9):772–8.
19. Sarkar M., Hennessy S., Yang Y. X. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008; 149(6):391–8.
20. Herzig S.J., Howell M. D., Ngo L. H., Marcantonio E. R. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. Jama. 2009;301(20):2120–8.
21. Laine L., Ahnen D., McClain C., Solcia E., Walsh J. H. Review article: potential gastrointestinal effects of longterm acid suppression with proton pump inhibitors. Aliment Pharmacol Th er. 2000;14(6):651–68.
22. Ali T., Roberts D. N., Tierney W. M. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122(10):896–903.
23. Vestergaard P., Rejnmark L., Mosekilde L. Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture. Calcif Tissue Int. 2006;79(2):76–83.
24. Yu E., Blackwell T., Ensrud K., et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83(4):251–9.
25. Targownik L.E., Lix L. M., Metge C. J., Prior H. J., Leung S., Leslie W. D. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319–26.
26. Corley D.A., Kubo A., Zhao W., Quesenberry C. Proton Pump Inhibitors and Histamine-2 Receptor Antagonists Are Associated With Hip Fractures Among At-Risk Patients. Gastroenterology. 2010;139(1):93–101.
27. FDA Drug Safety Communication. Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. Rockville, MD: U. S. Food and Drug Administration; [Accessed July 5, 2010]. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/u.cm213206.htm.
28. Elaine W. Yu., Scott R., Bauer B. S., Bain P. A., Bauer D. C. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med. 2011 Jun; 124(6): 519–526. doi: 10.1016/j.amjmed.2011.01.007.
29. Recker R. R. Calcium absorption and achlorhydria. N Engl J Med. 1985;313(2):70–3.
30. Tuukkanen J., Vaananen H. K. Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int. 1986;38(2):123–5.
31. Kocsis I., Arato A., Bodanszky H., et al. Short-term omeprazole treatment does not influence biochemical parameters of bone turnover in children. Calcif Tissue Int. 2002;71(2):129–32.
32. Mizunashi K., Furukawa Y., Katano K., Abe K. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53(1):21–5.
33. Hansen K.E., Jones A. N., Lindstrom M. J., et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res. 2010 Dec; 25(12): 2786–2795.
34. Kirkpantur A., Altun B., Arici M., Turgan C. Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients. Int J Clinical Practice. 2009;63(2):261–8.
35. Targownik L.E., Lix L. M., Leung S., Leslie W. D. Proton Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss. Gastroenterology. 2010 Mar;138(3):896–904. doi: 10.1053/j.gastro.2009.11.014. Epub 2009 Nov 18.
36. Dharmarajan T.S., Kanagala M. R., Murakonda P., Lebelt A. S., Norkus E. P. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008; 9(3): 162–7.
37. Valuck R.J., Ruscin J. M. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol. 2004; 57(4):422–8.
38. McLean R.R., Jacques P. F., Selhub J., et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med. 2004;350(20):2042–9.
39. Gerdhem P., Ivaska K. K., Isaksson A, et al. Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res. 2007;22(1):127–34.
40. Epstein M., McGrath S., Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355(17):1834–6.
41. Faulhaber G.A., Furlanetto T. W. Could magnesium depletion play a role on fracture risk in PPI users? Arch Intern Med. 2010 Oct 25;170(19):1776. doi: 10.1001/archinternmed.2010.374.
42. Brozek W., Reichardt B., Zwerina J., Dimai H. P., Klaushofer K., Zwettlera E. Higher dose but not low dose proton pump inhibitors are associated with increased risk of subsequent hip fractures after first hip fracture: A nationwide observational cohort study. Bone Rep. 2019 Jun; 10: 100204. doi: 10.1016/j.bonr.2019.100204.
43. Poly T.N., Islam M. M., Yang H. C., Wu C. C., Li Y. J. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019 Jan;30(1):103–114. doi: 10.1007/s00198–018–4788-y.
44. Haenisch B., von Holt K., Wiese B., et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci 2015; 265: 419–428.
45. Arai N., Nakamizo T., Ihara H., et al. Histamine H2-blocker and proton pump inhibitor use and the risk of pneumonia in acute stroke: a retrospective analysis on susceptible patients. P LoS One 2017; 12(1): e0169300.
46. Momosaki R., Yasunaga H., Matsui H., et al. Proton pump inhibitors versus histamine-2 receptor antagonists and risk of pneumonia in patients with acute stroke. J Stroke Cerebrovasc Dis 2016; 25(5): 1035–1040.
47. Bateman B.T., Bykov K., Choudhry N. K., et al. Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. BMJ 2013; 347: f5416.
48. Plotnikova E. Yu., Krasnova M. V., Krasnov K. A., Baranova E. N. The syndrome of excess bacterial overgrowth, which resulted from long intake of inhibitors of a proton pomp. Medical almanac. 2015; 1(36): 53–55.
49. Leonard J, Marshall J.K, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007; 102: 2047–2056.
50. Metz D. C. Clostridium difficile colitis: wash your hands before stopping the proton pump inhibitor. Am J Gastroenterol. 2008; 103: 2314–2316.
51. Thachil J. Overprescribing PPIs: time for a hospital antacid policy on Clostridium diffi cile. BMJ. 2008; 336: 109.
52. Food and Drug Administration (FDA) (2009) Updated Safety Information about a Drug Interaction between Clopidogrel Bisulfate and Omeprazole. Public Health Advisory. Available at: http://www.fda.gov/Drugs/Drug-Safety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcare-Professionals/PublicHealth Advisories/ucm190825.htm (accessed 15 December 2011).
53. Heidelbaugh J.J., Kim A. H., Chang R., Walker P. C. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol. 2012 Jul; 5(4): 219–232. doi: 10.1177/1756283X12437358.
54. Shiraki M., Yamasaki K., Ishiyama H., et al. Healing promoting effect of proamipide, a novel drug that increases gastric defense mechanisms, on acetic acid-induced gastric ulcers in the rat. Nippon Yakurigaku Zasshi. 1988; 92: 389–95.
55. Yamasaki K., Ishiyama H., Imaizumi T., et al. Effect of OPC-12759, a novel antiulcer agent, on chronic and acute experimental gastric ulcer, and gastric secretion in rats. Jap J Pharmacol. 1989; 49: 441–8.
56. Kleine A., Kluge S., Peskar B. M. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci. 1993; 38: 1441–9.
57. Ishiyama H., Yamasaki K., Kanbe T. Effect of proamipide (OPC-12759) on gastric mucus secretion in rats. Jpn Pharmacol Ther. 1988; 16: 4103–9.
58. Tarnawski A., Arakawa T., Kobayashi K. Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci. 1998; 43: 90S-8S.
59. Watanabe S., Wang X., Hirose M., et al. Rebamipide prevented delay of wound repair induced by hydrogen peroxide and suppressed apoptosis of gastric epithelial cells in vitro. Dig Dis Sci. 1998; 43: 107S-12S.
60. Yoshikawa T., Naito Y., Nakamura S., et al. Effect of rebamipide on lipid peroxidation and gastric mucosal injury induced by indometacin in rats. Arzneim Forsch / Drug Res. 1993; 43: 1327–30.
61. Suzuki M., Miura S., Mori M., et al. Rebamipide, a novel antiulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants. Gut. 1994; 35: 1375–8.
62. Aihara M., Azuma A., Takizawa H., et al. Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines. Dig Dis Sci. 1998; 43: 174S-80S.
63. Arakawa T., Kobayashi K., Yoshikawa T., et al. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998; 43: 5S-13S.
64. Arakawa T., Kobayashi K. Quality of ulcer healing: a new concept to rank healed peptic ulcers. Gastroenterol Jpn. 1993; 28: 158–62.
65. Arakawa T., Nebiki H., Higuchi K., et al. Rebamipide, a gastroprotective drug, improves quality of healing and decreases recurrence of gastric ulcer without affecting Helicobacter pylori status [abstract]. Gastrointest Endosc. 1997; 45: AB87.
66. Naito Y., Yoshikawa T., Iinuma S., Yagi N., Matsuyama K., Boku Y., et al. Rebamipide protects against indomethacininduced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study. Dig Dis Sci. 1998;43(9):83S-9S.
67. Kim H.K., Kim J. I., Kim J. K., Han J. Y., Park S. H., Choi K. Y., et al. Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig Dis Sci. 2007;52(8):1776–82. doi: 10.1007/s10620–006–9367-y.
68. Terano A., Arakawa T., Sugiyama T., Suzuki H., Joh T., Yoshikawa T., et al. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol. 2007;42(8):690–3. doi: 10.1007/s00535–007–2076–2.
69. Kobayashi M., Takeuchi M., Hashimoto S., Mizuno K., Sato Y., Narisawa R., et al. Contributing factors to gastric ulcer healing after endoscopic submucosal dissection including the promoting effect of rebamipide. Dig Dis Sci. 2012;57(1):119–26. doi: 10.1007/s10620–011–1850–4.
70. Kim J.H., Park S. H., Cho C. S., Lee S. T., Yoo W. H., Kim S. K., et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory druginduced mucosal toxicity. Gut Liver. 2014;8(4):371–9. doi: 10.5009/gnl.2014.8.4.371.
71. Kurokawa S., Katsuki S., Fujita T., Saitoh Y., Ohta H., Nishikawa K., et al. A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol. 2014;49(2):239–44. doi: 10.1007/s00535–013–0805–2.
72. Tozawa K., Oshima T., Okugawa T., Ogawa T., Ohda Y., Tomita T., et al. A randomized, double-blind, placebocontrolled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel. Dig Dis Sci. 2014;59(8):1885–90. doi: 10.1007/s10620–014–3108–4.
73. Plotnikova E. Yu., Gracheva T. Yu. Erosive and ulcer damages of digestive tract and prostaglandins: problem duet. Reference book by the polyclinic doctor. 2016; 4: 32–37.
74. Koyama N., Sasabe H., Miyamoto G. Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver. Xenobiotica. 2002 Jul;32(7):573–86.
Review
For citations:
Plotnikova E.Yu., Vologdanina L.G., Korotkevich A.G., Gracheva T.Yu. Gastroprotection in the treatment of erosive and ulcerative lesions of the stomach and small intestine. Experimental and Clinical Gastroenterology. 2019;(9):17-26. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-169-9-17-26
Views:
662
Email this article 